thiazoles has been researched along with End Stage Liver Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al, M; Armstrong, N; Buksnys, T; Büyükkaramikli, N; Drachen, T; Duffy, S; Huertas Carrera, V; Kleijnen, J; Penton, H; Raatz, H; Riemsma, R; Ryder, S; Shah, D; Swift, S; Wetzelaer, P; Worthy, G | 1 |
| Ishibashi, K; Kaneko, T; Takano, Y | 1 |
| Katsube, T; Shimizu, R; Wajima, T | 1 |
| Ferry, J; Hussein, Z; Nomoto, M | 1 |
| Aschenbrenner, DS | 1 |
1 review(s) available for thiazoles and End Stage Liver Disease
| Article | Year |
|---|---|
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Topics: Bayes Theorem; Cinnamates; Clinical Trials as Topic; Cost-Benefit Analysis; End Stage Liver Disease; Humans; Models, Economic; Platelet Transfusion; Quality-Adjusted Life Years; Receptors, Thrombopoietin; Secondary Care; Technology Assessment, Biomedical; Thiazoles; Thiophenes; Thrombocytopenia | 2020 |
4 other study(ies) available for thiazoles and End Stage Liver Disease
| Article | Year |
|---|---|
Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
Topics: Aged; Blood Loss, Surgical; Cinnamates; End Stage Liver Disease; Endoscopy; Female; Humans; Lumbar Vertebrae; Spinal Fractures; Thiazoles; Thrombocytopenia | 2021 |
Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease.
Topics: Blood Platelets; Cinnamates; Computer Simulation; End Stage Liver Disease; Humans; Receptors, Thrombopoietin; Thiazoles; Thrombopoiesis | 2021 |
Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Computer Simulation; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; End Stage Liver Disease; Female; Humans; Male; Middle Aged; Models, Biological; Thiazoles; Thiophenes; Thrombocytopenia; Young Adult | 2018 |
First Drug Approved to Reduce Bleeding Risk During Medical Procedures in Patients with Chronic Liver Disease.
Topics: Drug Approval; End Stage Liver Disease; Humans; Receptors, Thrombopoietin; Thiazoles; Thiophenes; Thrombocytopenia | 2018 |